公开(公告)号：EP2216045A1

公开(公告)日：2010-08-11

申请号：EP08845509.2

申请日：2008-10-17

申请人： Centro De Ingenieria Genetica Y Biotecnologia

发明人： QUINTANA VÁZQUEZ, Diógenes ,  MENENDEZ MEDINA, Tamara ,  ÁLVAREZ ACOSTA, Anabel ,  CRUZ LEAL, Yoelys ,  GUILLEN NIETO, Gerardo, Enrique

IPC分类号： A61K39/10 ,  A61P31/04 ,  C07K14/235

CPC分类号： G01N33/56911 ,  A61K39/00 ,  A61K39/099 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/53 ,  C07K14/235 ,  Y02A50/466

摘要： The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.

摘要翻译： 本发明涉及生物医学领域。 它包括Pertactin蛋白（Prn）的工程，并将其用作细菌疫苗的一部分，更确切地说，作为针对博德特氏菌的无细胞疫苗的一部分。 工程化的Prn分子在其结构上包括来自不同的百日咳杆菌菌株的结构，并且当测定为疫苗时诱导具有保护能力和调理吞噬活性的免疫应答，高于其他预先存在的疫苗产生的疫苗。 本发明的工程化Prn变体可应用于人兽药。

公开(公告)号：EP1982994A2

公开(公告)日：2008-10-22

申请号：EP06828471.0

申请日：2006-12-28

申请人： CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA

发明人： MENÉNDEZ MEDINA, Tamara ,  CRUZ LEAL, Yoelys ,  REYES ACOSTA, Osvaldo ,  GARAY PÉREZ, Hilda, Elisa ,  GUILLÉN NIETO, Gerardo, Enrique ,  COIZEAU RODRÍGUEZ, Edelgis ,  SANTIAGO VISPO, Nelson, Francisco ,  CHINEA SANTIAGO, Glay

IPC分类号： C07K14/22 ,  A61K38/16 ,  G01N33/68

CPC分类号： C07K14/22 ,  A61K39/00

摘要： The present invention is related with the pharmaceutical industry and the biotechnology, specifically with vaccine antigens applied against bacterial, viral, cancerous or another origin diseases. Development of pharmaceuticals formulations able to protect or to increase the protective spectrum of already developed vaccines and to extend it against several pathogens, using as target for the immune response, carbohydrates composed of repeated units of (α 2-8) linked N-replaced neuraminic acid. Several peptides were isolated and identified as molecular mimetics of the capsular polysaccharide form serogroup B of Neisseria meningitidis, which is composed of repeated units of (α 2-8) linked N-acetyl neuraminic acid. The immunogenicity of peptides was evaluated in animal biomodels, demonstrating their value as antigens able to induce the production of antibodies able of specifically recognize the bacterium N. meningitidis from serogroup B and of showing bactericidal activity against the same one. The resulting formulations of are applicable in the pharmaceutical industry as vaccine formulations for human use.

摘要翻译： 本发明涉及制药工业和生物技术，特别是针对细菌，病毒，癌性或其它起源疾病的疫苗抗原。 开发能够保护或增加已经开发的疫苗的保护范围并将其扩展到几种病原体的药物制剂，其用作免疫应答的靶标，由（±2-8）连接的N-取代的神经氨酸的重复单位组成的碳水化合物 酸。 分离出几种肽，鉴定为脑膜炎奈瑟菌脑膜炎血清群B的荚膜多糖的分子模拟物，其由重复单位的（±2-8）连接的N-乙酰神经氨酸组成。 在动物生物模型中评估肽的免疫原性，证明其作为能够诱导产生能够特异性识别来自血清群B的脑膜炎奈瑟菌细菌的抗体的抗原的值，并且对相同抗体具有杀菌活性。 所得到的制剂可用于制药工业，作为用于人类的疫苗制剂。